Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert McShane

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Health and Quality of Life Outcomes|August 16, 2020
Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8)Apostolos Tsiachristas, Caroline M Potter, Stephen Rocks, et al.
Trials|October 25, 2013
Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trialIracema Leroi, John Woolham, Rebecca Gathercole, et al.
Journal of Affective Disorders|February 15, 2020
Development of the Ketamine Side Effect Tool (KSET)Brooke Short, Vanessa Dong, Verònica Gálvez, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Bjpsych Open|October 6, 2016
Ketamine: stimulating antidepressant treatment?Gin S Malhi, Yulisha Byrow, Frederick Cassidy, et al.
JAMA Neurology|November 19, 2019
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical TrialRobert Howard, Olga Zubko, Rosie Bradley, et al.
Trials|March 27, 2016
Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trialNicky Atherton, Chris Bridle, Deborah Brown, et al.
Journal of Affective Disorders|April 11, 2022
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatryAdam Bayes, Brooke Short, Carlos A Zarate, et al.
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Health and Quality of Life Outcomes|August 16, 2020
Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8)Apostolos Tsiachristas, Caroline M Potter, Stephen Rocks, et al.
Trials|October 25, 2013
Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trialIracema Leroi, John Woolham, Rebecca Gathercole, et al.
Journal of Affective Disorders|February 15, 2020
Development of the Ketamine Side Effect Tool (KSET)Brooke Short, Vanessa Dong, Verònica Gálvez, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Bjpsych Open|October 6, 2016
Ketamine: stimulating antidepressant treatment?Gin S Malhi, Yulisha Byrow, Frederick Cassidy, et al.
JAMA Neurology|November 19, 2019
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical TrialRobert Howard, Olga Zubko, Rosie Bradley, et al.
Trials|March 27, 2016
Dementia and Physical Activity (DAPA) - an exercise intervention to improve cognition in people with mild to moderate dementia: study protocol for a randomized controlled trialNicky Atherton, Chris Bridle, Deborah Brown, et al.
Journal of Affective Disorders|April 11, 2022
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatryAdam Bayes, Brooke Short, Carlos A Zarate, et al.
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Pageof 7